Drop-In Replacement Steps: Leveraging Azetidine Constrained Geometry to Reduce CYP450 Metabolic Clearance vs Piperidine Analogs
When transitioning from piperidine-based scaffolds to the 1-Benzhydrylazetidin-3-amine structure, R&D teams often observe a marked reduction in CYP450-mediated metabolic clearance. The constrained geometry of the four-membered azetidine ring restricts conformational freedom, limiting the substrate's ability to adopt the bioactive conformation required for rapid oxidative metabolism. The steric bulk of the benzhydryl group further shields the azetidine nitrogen, reducing accessibility to metabolic enzymes. This dual mechanism of constrained geometry and steric shielding makes the scaffold
